Cowen & Co. upgraded Alimera Sciences Inc (NASDAQ:ALIM) from Market Perform to Outperform in a report released today.
- Updated: September 16, 2016
Cowen & Co. has upgraded Alimera Sciences Inc(NASDAQ:ALIM) from Market Perform to Outperform in a statement released on Friday September 16 2016.
Just yesterday Alimera Sciences Inc (NASDAQ:ALIM) traded 0.00% even at $1.52. Alimera Sciences Inc’s 50-day average is $1.66 and its 200-day moving average is $1.68. With the last close down 9.71% from the two hundred day moving average, compared to the S&P 500 Index which has fallen -0.01% over the date range. Trading volume was was down over the average, with 2,488 shares of ALIM changing hands under the typical 920,266 shares..
Recent Performance Graphic:
Alimera Sciences Inc has a one-year low of $1.01 and a 52 week high of $5.15 . Alimera Sciences Inc’s market capitalization is currently $0.0.
A total of 2 firms have issued a ratings update on ALIM. Zero rate the stock a strong buy, three analysts rate the stock a buy, 0 analysts rate the stock a hold, 0 rate the stock to underperform, and finally 0 analystsrate the company as sell with a consensus target price of $7.50
Brief Synopsis On Alimera Sciences Inc (NASDAQ:ALIM)
Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, and ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.